STERIS(US:STE) Globenewswireยท2025-05-14 20:30Financial Performance - Total revenue from continuing operations for Q4 FY2025 increased 4% to $1.5 billion compared to $1.4 billion in Q4 FY2024, with constant currency organic revenue growth of 6% [1][2] - For the full year FY2025, revenue from continuing operations rose 6% to $5.5 billion from $5.1 billion in FY2024, maintaining a constant currency organic revenue growth of 6% [2][9] - Net income from continuing operations for Q4 FY2025 was $146.5 million or $1.48 per diluted share, down from $152.9 million or $1.54 per diluted share in Q4 FY2024; adjusted net income for Q4 FY2025 was $270.3 million or $2.74 per diluted share, up from $240.1 million or $2.41 per diluted share in the prior year [3][4] Segment Performance - Healthcare revenue in Q4 FY2025 grew 5% to $1.1 billion, driven by a 13% increase in service revenue and a 6% rise in consumable revenue, despite a 4% decline in capital equipment revenue; operating income for this segment was $279.7 million, up from $245.2 million in the previous year [5] - Applied Sterilization Technologies (AST) revenue for Q4 FY2025 increased 9% to $273.9 million, with a 6% growth in service revenue; segment operating income rose to $122.2 million from $114.2 million year-over-year [6] - Life Sciences revenue in Q4 FY2025 decreased 7% to $149.5 million, primarily due to the divestiture of the CECS business; however, operating income slightly increased to $65.0 million from $64.5 million in the prior year [7] Cash Flow and Outlook - Net cash provided by operations for FY2025 was $1.15 billion, compared to $973.3 million in FY2024; free cash flow increased to $787.2 million from $620.3 million [8] - For FY2026, the company expects revenue from continuing operations to increase by 6-7%, with adjusted earnings per diluted share anticipated to be in the range of $9.90 to $10.15, reflecting a 7-10% increase compared to FY2025 [10][11]